查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1477349

鹼基編輯市場 - 全球產業規模、佔有率、趨勢、機會和預測，按產品和服務（產品、服務）、類型、目標基礎、應用、最終用戶、地區和競爭細分，2019 年-2029F

Base Editing Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Product & Service (Product, Services ), By Type, By Targeted Base, By Application, By End User, By Region, and By Competition, 2019-2029F
出版日期: | 出版商: TechSci Research | 英文 185 Pages | 商品交期: 2-3個工作天內

價格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

簡介目錄

2023 年，全球鹼基編輯市場價值為2.8102 億美元，預計到2029 年，預測期內將以15.64% 的複合年成長率實現令人印象深刻的成長。進步，為個體提供精確、高效的修飾。與 CRISPR-Cas9 等觸發容易出錯的修復機制的傳統技術不同，鹼基編輯直接在特定目標位點將一個 DNA 鹼基轉換為另一個鹼基。

市場概況
預測期 2025-2029
2023 年市場規模 28102萬美元
2029 年市場規模 6.696億美元
2024-2029 年複合年成長率 15.64%
成長最快的細分市場 gRNA設計
最大的市場 北美洲

這種創新方法涉及包含催化失活Cas蛋白（例如Cas9或Cas12a）和脫氨酶（例如胞苷脫氨酶或腺嘌呤脫氨酶）的融合蛋白。 Cas蛋白引導鹼基編輯器到達目標DNA序列，而脫氨酶則催化鹼基的化學轉化。在短 RNA 分子的引導下，鹼基編輯器可以精確修飾單一鹼基，無需誘導 DSB 或依賴同源定向修復機制。與 CRISPR-Cas9 相比，鹼基編輯具有多種優勢，包括高效率、特異性和最小的脫靶效應。這些優點使其成為糾正點突變、引入特定核苷酸變化和調節基因功能的有前途的工具。

包括鹼基編輯在內的基因組編輯技術的不斷發展，已將其應用擴展到各個領域。在人類治療中，鹼基編輯顯示出透過針對致病突變來解決遺傳性疾病、慢性疾病和遺傳性疾病的潛力。此外，鹼基編輯在生物技術中也有應用，促進功能基因體學研究、藥物發現和生物生產。在農業中，鹼基編輯可望改善作物、抗病和性狀修飾。鹼基編輯技術正在推動基因組編輯領域的創新，為醫療保健、生物技術和農業領域的多種應用提供精確的解決方案。隨著研究和開發工作的繼續，鹼基編輯預計將在解決遺傳疾病和推進多個行業的科學發現方面發揮重要作用。

主要市場促進因素

基因組編輯技術的進步

遺傳性疾病和慢性病的發生率上升

擴大生物技術和農業的應用

主要市場挑戰

脫靶效應

效率和精度

主要市場趨勢

交付方式的進步

細分市場洞察

目標基地洞察

最終使用者見解

區域洞察

目錄

第 1 章：產品概述

第 2 章：研究方法

第 3 章：執行摘要

第 4 章：客戶之聲

第 5 章：全球鹼基編輯市場展望

  • 市場規模及預測
    • 按價值
  • 市佔率及預測
    • 按產品和服務（產品、服務）
    • 按類型（DNA鹼基編輯、RNA鹼基編輯）
    • 依目標鹼基（胞嘧啶鹼基編輯、腺嘌呤鹼基編輯）
    • 依應用（藥物發現與開發、農業、獸醫）
    • 按最終用戶（製藥和生物技術公司、學術和研究機構、合約研究組織）
    • 按地區
    • 按公司分類 (2023)
  • 市場地圖

第 6 章：北美基地編輯市場展望

  • 市場規模及預測
    • 按價值
  • 市佔率及預測
    • 按產品和服務
    • 按類型
    • 按目標基地
    • 按申請
    • 按最終用戶
    • 按國家/地區
  • 北美：國家分析
    • 美國
    • 加拿大
    • 墨西哥

第 7 章：歐洲基礎編輯市場展望

  • 市場規模及預測
    • 按價值
  • 市佔率及預測
    • 按產品和服務
    • 按類型
    • 按目標基地
    • 按申請
    • 按最終用戶
    • 按國家/地區
  • 歐洲：國家分析
    • 德國
    • 英國
    • 義大利
    • 法國
    • 西班牙

第 8 章：亞太地區基地編輯市場展望

  • 市場規模及預測
    • 按價值
  • 市佔率及預測
    • 按產品和服務
    • 按類型
    • 按目標基地
    • 按申請
    • 按最終用戶
    • 按國家/地區
  • 亞太地區：國家分析
    • 中國
    • 印度
    • 日本
    • 韓國
    • 澳洲

第 9 章：南美洲基地編輯市場展望

  • 市場規模及預測
    • 按價值
  • 市佔率及預測
    • 按產品和服務
    • 按類型
    • 按目標基地
    • 按申請
    • 按最終用戶
    • 按國家/地區
  • 南美洲：國家分析
    • 巴西
    • 阿根廷
    • 哥倫比亞

第 10 章：中東和非洲基地編輯市場展望

  • 市場規模及預測
    • 按價值
  • 市佔率及預測
    • 按產品和服務
    • 按類型
    • 按目標基地
    • 按申請
    • 按最終用戶
    • 按國家/地區
  • MEA：國家分析
    • 南非
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國

第 11 章：市場動態

  • 促進要素
  • 挑戰

第 12 章：市場趨勢與發展

  • 併購（如有）
  • 產品發布（如有）
  • 最近的發展

第 13 章：波特的五力分析

  • 產業競爭
  • 新進入者的潛力
  • 供應商的力量
  • 客戶的力量
  • 替代產品的威脅

第14章：競爭格局

  • Danaher Corporation
  • Merck KGaA
  • Maravai Intermediate Holdings, LLC
  • GenScript Biotech Corporation
  • Beam Therapeutics Inc.
  • Intellia Therapeutics, Inc.
  • Bio Palette Co., Ltd
  • EdiGene, Inc.
  • ProQR Therapeutics NV
  • KromaTiD, Inc.

第 15 章：策略建議

第16章調查會社について,免責事項

簡介目錄
Product Code: 23862

Global Base Editing Market was valued at USD 281.02 million in 2023 and expected to experience an impressive growth in the forecast period at a CAGR of 15.64% through 2029. Base editing represents a groundbreaking advancement in genome editing technology, offering precise and efficient modifications to individual nucleotides within DNA sequences without inducing double-stranded breaks (DSBs). Unlike conventional techniques like CRISPR-Cas9, which trigger error-prone repair mechanisms, base editing directly converts one DNA base to another at specific target sites.

Market Overview
Forecast Period2025-2029
Market Size 2023USD 281.02 Million
Market Size 2029USD 669.60 Million
CAGR 2024-202915.64%
Fastest Growing SegmentgRNA Design
Largest MarketNorth America

This innovative approach involves a fusion protein comprising a catalytically inactive Cas protein (e.g., Cas9 or Cas12a) and a deaminase enzyme (e.g., cytidine deaminase or adenine deaminase). The Cas protein guides the base editor to the target DNA sequence, while the deaminase enzyme catalyzes the chemical conversion of bases. Guided by a short RNA molecule, the base editor precisely modifies single bases without inducing DSBs or relying on homology-directed repair mechanisms. Base editing offers several advantages, including high efficiency, specificity, and minimal off-target effects compared to CRISPR-Cas9. These benefits make it a promising tool for correcting point mutations, introducing specific nucleotide changes, and modulating gene function.

The continuous evolution of genome editing technologies, including base editing, has expanded their applications across various fields. In human therapeutics, base editing shows potential for addressing genetic disorders, chronic diseases, and inherited conditions by targeting disease-causing mutations. Additionally, base editing has applications in biotechnology, facilitating functional genomics studies, drug discovery, and bioproduction. In agriculture, base editing holds promise for crop improvement, disease resistance, and trait modification. Base editing technology is driving innovation in genome editing, offering precise solutions for diverse applications in healthcare, biotechnology, and agriculture. As research and development efforts continue, base editing is expected to play a significant role in addressing genetic diseases and advancing scientific discovery across multiple industries.

Key Market Drivers

Advancements in Genome Editing Technologies

The CRISPR-Cas9 system has revolutionized genome editing, offering researchers a powerful tool for precise and efficient DNA manipulation. Derived from bacterial immune mechanisms, this system enables targeted modifications to specific DNA sequences, making it widely adopted in genetic engineering and research. Base editing technologies, such as cytosine base editors (CBEs) and adenine base editors (ABEs), further enhance genome editing capabilities by enabling precise changes to individual DNA bases without inducing double-stranded breaks. Prime editing, a recent breakthrough, combines CRISPR-Cas9 with reverse transcriptase to insert, delete, or substitute DNA sequences with unmatched flexibility and accuracy, revolutionizing traditional methods.

Efforts to enhance genome editing specificity have led to the development of strategies like modifying Cas9 enzymes and optimizing guide RNA design. These advancements minimize off-target effects, ensuring precision in genetic modifications. Improvements in delivery systems, including viral vectors and nanoparticles, facilitate targeted delivery of genome editing tools into cells and tissues, enhancing efficiency and reducing immune responses.

Multiplex genome editing technologies enable simultaneous modifications of multiple genomic loci within a single cell, allowing for complex genetic modifications and functional genomics studies. In vivo genome editing technologies offer therapeutic potential for genetic diseases, cancer, and other disorders by directly modifying the genome within living organisms. Advances in delivery methods and gene editing tools have enabled the exploration of in vivo editing approaches in preclinical and clinical settings, driving advancements in the global base editing market.

Rising Incidence of Genetic Disorders and Chronic Diseases

The CRISPR-Cas9 system, originating from bacterial immune mechanisms, has revolutionized genome editing, providing researchers with a precise and efficient tool for targeted genetic modifications. Unlike traditional methods, CRISPR-Cas9 enables the precise targeting of specific DNA sequences, making it invaluable in genetic engineering and research. Base editing technologies have further enhanced genome editing capabilities by allowing for precise changes to individual DNA bases without inducing double-stranded breaks. Techniques like cytosine base editors (CBEs) and adenine base editors (ABEs) facilitate single-nucleotide substitutions, significantly expanding the scope of genome editing applications.

Prime editing represents a recent breakthrough in genome editing, combining the CRISPR-Cas9 system with reverse transcriptase to enable precise DNA sequence alterations without the need for double-stranded breaks. Prime editing offers greater flexibility and accuracy compared to traditional methods, opening new possibilities for genetic manipulation.

Efforts to enhance the specificity of genome editing tools have led to various strategies, including modifying Cas9 enzymes, optimizing guide RNA design, and developing high-fidelity editing platforms. These advancements aim to minimize off-target effects and improve the precision of genome editing technologies.

Delivery systems play a crucial role in the efficient and targeted delivery of genome editing tools into cells and tissues. Viral vectors, nanoparticles, lipid nanoparticles, and other delivery vehicles have been optimized to enhance delivery efficiency and reduce immune responses associated with genome editing applications.

Multiplex genome editing technologies enable the simultaneous modification of multiple genomic loci within a single cell, facilitating complex genetic modifications and functional genomics studies. Techniques such as CRISPR arrays, multiplexed guide RNA libraries, and combinatorial genome editing strategies have been developed to enable multiplex genome editing.

In vivo genome editing technologies allow for direct modification of the genome within living organisms, offering potential therapeutic applications for genetic diseases, cancer, and other disorders. Advances in delivery methods and gene editing tools have enabled the exploration of in vivo editing approaches in preclinical and clinical settings. The continuous advancements in genome editing technologies, delivery systems, and multiplex editing approaches have expanded the scope and potential applications of genome editing. These innovations hold promise for addressing a wide range of genetic diseases and disorders, paving the way for advancements in medicine, agriculture, and biotechnology.

Expanding Applications in Biotechnology and Agriculture

Base editing, a transformative genome editing technology, offers researchers precise tools for manipulating DNA sequences with unparalleled accuracy. Its applications span various fields, contributing to advancements in basic research, drug discovery, bioproduction, agriculture, and animal breeding. In basic research, base editing enables the precise introduction of mutations or modifications to individual nucleotides, facilitating the study of gene function, cellular pathways, and disease mechanisms. This capability aids in uncovering fundamental biological processes and unraveling the complexities of genetic regulation.

Base editing's role in drug discovery is invaluable. By creating cellular and animal models with precise genetic modifications, researchers can investigate the effects of candidate drugs on specific genetic backgrounds. This approach accelerates the identification of novel drug targets, optimization of therapeutic interventions, and streamlining of the drug discovery pipeline.

In bioproduction and industrial biotechnology, base editing enhances microbial strain optimization and bioprocess efficiency. By engineering microorganisms with desired traits, such as increased productivity or metabolic efficiency, base editing improves processes like biofuel production, bioremediation, and industrial fermentation, thereby advancing sustainable biotechnological practices.

Base editing also holds promise for precision breeding and genome editing in livestock animals. By introducing targeted genetic modifications, such as disease resistance or improved productivity, base editing technologies enable the development of livestock breeds with desirable characteristics, benefiting animal health, welfare, and agricultural productivity. Support from regulatory agencies and policymakers is crucial for the responsible adoption of base editing technologies. Clear regulatory frameworks provide certainty and facilitate the integration of base editing into research, product development, and commercialization efforts. Collaborations among academic institutions, biotechnology companies, agricultural organizations, and government agencies drive innovation and technology transfer in the field of base editing. These partnerships foster the exchange of knowledge, resources, and expertise, accelerating the development and deployment of base editing technologies in biotechnology and agriculture sectors.

Base editing represents a powerful toolset with wide-ranging applications across diverse fields. As research progresses and regulatory support strengthens, the demand for base editing technologies is expected to soar, further driving innovation and advancements in biotechnology, agriculture, and beyond.

Key Market Challenges

Off-Target Effects

Off-target effects occur when base editing tools inadvertently modify DNA sequences other than the intended target site. These unintended mutations can result in genetic alterations that may have unpredictable consequences, including potential harm to the organism or unintended changes to gene function. Off-target effects raise safety concerns, particularly in therapeutic applications of base editing. The introduction of unintended mutations could lead to adverse effects, including the development of new diseases, disruptions to normal cellular processes, or unintended changes to the organism's phenotype. Off-target effects can compromise the specificity of base editing technologies, limiting their accuracy and reliability in genome editing applications.

Minimizing off-target effects is essential for ensuring the precision and efficacy of base editing tools, particularly in therapeutic contexts where safety is paramount. Identifying potential off-target sites is challenging due to the complexity of genome sequences and the limitations of computational algorithms used for predicting off-target effects. Experimental validation is often required to assess the specificity of base editing tools accurately, which can be time-consuming and resource intensive. Concerns about off-target effects may impact the regulatory approval process for base editing therapies and products. Regulatory agencies require comprehensive safety and efficacy data, including assessments of off-target effects, to evaluate the risks and benefits of base editing technologies and ensure their safe use in clinical settings. Addressing off-target effects requires the development of base editing tools with improved editing specificity and reduced propensity for unintended mutations. Researchers are actively exploring novel strategies and engineering approaches to enhance the specificity of base editing platforms and minimize off-target effects.

Efficiency and Precision

Base editing techniques aim to precisely modify specific DNA bases within the genome. However, achieving high editing efficiency-meaning the percentage of cells in which the desired edit is successfully made-can be challenging. Enhancing editing efficiency is crucial for ensuring that a sufficient proportion of target cells undergo the desired genetic modification. Alongside optimizing efficiency, maintaining precision is paramount to minimize off-target effects. Off-target effects occur when base editors inadvertently modify DNA sequences other than the intended target site. Improving the precision of base editing tools helps mitigate the risk of unintended mutations and ensures the accuracy of genetic modifications. The efficiency and precision of base editing can vary depending on the sequence context surrounding the target site. Some DNA sequences may be more amenable to editing than others, while certain sequence motifs may be prone to off-target effects. Understanding and overcoming sequence context dependence is essential for optimizing base editing outcomes across different genomic regions. Accessibility of target sites within the genome can impact the efficiency and precision of base editing. Regions of the genome that are highly compacted or inaccessible may pose challenges for base editors to access and modify. Overcoming barriers to target site accessibility is necessary for achieving efficient and precise editing outcomes.

Efficient delivery of base editing components, including base editor proteins and guide RNAs, to target cells and tissues is crucial for achieving optimal editing efficiency and precision. Developing effective delivery methods that ensure sufficient uptake and activity of base editing tools in target cells remains a challenge in the field. Achieving a balance between editing specificity and efficiency is essential. Increasing specificity may require additional engineering to minimize off-target effects, which can sometimes come at the expense of editing efficiency. Striking the right balance between specificity and efficiency is necessary to optimize base editing outcomes for various applications.

Key Market Trends

Advancements in Delivery Methods

Viral vectors, like adeno-associated viruses (AAVs) and lentiviruses, are widely employed for delivering base editing components into target cells. Continuous advancements in viral vector design and engineering have led to enhancements in vector stability, transduction efficiency, and tissue specificity, thereby enabling more precise and effective delivery of base editing tools. Non-viral delivery systems, including lipid nanoparticles, polymer-based nanoparticles, and cell-penetrating peptides, provide alternative approaches for delivering base editing components. These systems are often more cost-effective and scalable than viral vectors and can be customized to achieve cell type-specific targeting and controlled release of base editing payloads. Nanotechnology-based methods leverage the unique properties of nanoparticles to facilitate the delivery of base editing components across biological barriers, such as the cell membrane and the blood-brain barrier.

Functionalization of nanoparticles with targeting ligands and protective coatings enhances cellular uptake, reduces immunogenicity, and improves payload stability. Exosomes, extracellular vehicles released by cells, hold promise as natural vehicles for delivering base editing components to target cells.

Exosomes can be engineered to display targeting ligands on their surface, enabling targeted delivery to specific cell types and tissues while minimizing off-target effects. Physical methods, including electroporation, microinjection, and ultrasound-mediated delivery, enable direct introduction of base editing components into target cells through mechanical or electrical means. These methods offer rapid and efficient delivery of base editing tools without the need for viral vectors or complex formulations, making them appealing for certain research and therapeutic applications. In vivo delivery strategies aim to deliver base editing components directly into target tissues and organs within living organisms. Advancements in in vivo delivery methods include tissue-specific targeting strategies, systemic administration routes, and biocompatible delivery vehicles designed to navigate physiological barriers and achieve efficient uptake and distribution of base editing payloads.

Segmental Insights

Targeted Base Insights

Based on the targeted base, the adenine base editing segment is poised for rapid growth in the Global Base Editing Market, driven by its significant advancements in genome editing technology. This innovative approach allows for precise and efficient modification of adenine (A) bases within the DNA sequence, expanding the capabilities of researchers and biotechnologists. Adenine base editing complements existing technologies like cytosine base editors (CBEs) and CRISPR-Cas9 by enabling the targeting of different DNA base pairs, broadening the scope of genetic mutations that can be corrected.

The versatility of adenine base editing enhances its applicability across various genetic conditions and therapeutic targets, fostering its adoption in both research and clinical settings. Engineered adenine base editing platforms prioritize minimizing off-target effects, thereby improving the safety and specificity of genome editing procedures. This heightened precision reduces the risk of unintended mutations, bolstering the reliability of adenine base editing technologies for therapeutic applications.

Adenine base editing holds significant promise for developing novel gene therapies and treatments for genetic diseases. By enabling precise modifications to the DNA sequence, adenine base editing can potentially offer cures or alleviate symptoms for patients with inherited disorders. Ongoing research focuses on optimizing delivery methods for adenine base editing tools to ensure efficient and targeted delivery to specific cell types and tissues, further enhancing its feasibility and scalability for therapeutic applications.

End User Insights

The pharmaceutical & biotechnology companies segment is projected to experience rapid growth in the Global Base Editing Market during the forecast period. Pharmaceutical and biotechnology companies are investing heavily in R&D to develop novel therapies and treatments for various diseases and medical conditions. Base editing technologies offer significant potential for advancing drug discovery and development processes by enabling precise modifications to the genome to target disease-causing mutations. Base editing represents a significant advancement in genome editing technology, allowing for precise and efficient modification of DNA bases without inducing double-stranded breaks. Pharmaceutical and biotechnology companies are increasingly adopting base editing techniques to develop next-generation therapies with improved precision and efficacy. Base editing holds promise for a wide range of therapeutic applications, including the treatment of genetic disorders, cancer, infectious diseases, and autoimmune conditions.

Pharmaceutical companies are leveraging base editing technologies to develop gene therapies, cell therapies, and gene-modified cell lines for therapeutic purposes. Base editing enables the simultaneous editing of multiple genes with high precision, allowing researchers to target complex genetic pathways and disease mechanisms. This capability is particularly valuable for pharmaceutical companies engaged in drug discovery and development, as it facilitates the identification of novel drug targets and the optimization of therapeutic interventions. Base editing technologies can streamline the drug development process by providing insights into disease biology, identifying potential drug targets, and facilitating the development of more effective and targeted therapies. Pharmaceutical companies are integrating base editing into their drug discovery pipelines to accelerate the identification and development of novel therapeutics.

Regional Insights

North America emerged as the dominant player in the Global Base Editing Market in 2023. North America, particularly the United States, boasts a strong ecosystem of research institutions, universities, and biotechnology companies that are at the forefront of developing base editing technologies. The region has a rich history of scientific innovation and significant investments in biotechnology research and development. North America has a robust funding environment for biotechnology research and innovation. Government agencies, private foundations, venture capitalists, and corporate investors provide substantial funding to support research projects and the development of cutting-edge technologies, including base editing.

Many of the leading biotechnology companies specializing in genome editing and gene therapy are based in North America. These companies have the resources, expertise, and infrastructure to advance base editing technologies from the laboratory to commercialization. North America has well-established regulatory frameworks and supportive policies for biotechnology and genomic research. Clear regulations and guidelines provide clarity and certainty for researchers and companies developing base editing technologies, facilitating innovation and commercialization.

Key Market Players

Danaher Corporation

Merck KGaA

Maravai Intermediate Holdings, LLC

GenScript Biotech Corporation

Beam Therapeutics Inc.

Intellia Therapeutics, Inc.

Bio Palette Co., Ltd.

EdiGene, Inc.

ProQR Therapeutics N.V.

KromaTiD, Inc.

Report Scope:

In this report, the Global Base Editing Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Base Editing Market, By Product & Service:

    By Product

Platform

Kits & Reagents

Plasmids

Base Editing Libraries

    By Services

gRNA Design

Cell line engineering

Other Service

Base Editing Market, By Type:

    DNA base editing RNA base editing

Base Editing Market, By Targeted Base:

    Cytosine base editing Adenine base editing

Base Editing Market, By Application:

    Drug Discovery & Development Agriculture Veterinary

Base Editing Market, By End User:

    Pharmaceutical & Biotechnology Companies Academic & Research Institutes Contract Research Organizations

Base Editing Market, By Region:

    North America

United States

Canada

Mexico

    Europe

Germany

United Kingdom

France

Italy

Spain

    Asia-Pacific

China

Japan

India

Australia

South Korea

    South America

Brazil

Argentina

Colombia

    Middle East & Africa

South Africa

Saudi Arabia

UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Base Editing Market.

Available Customizations:

Global Base Editing market report with the given market data, Tech Sci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Base Editing Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Product & Service (Product, Services)
      • 5.2.1.1. By Product (Platform, Kits & Reagents, Plasmids, Base Editing Libraries)
      • 5.2.1.2. By Services (gRNA Design, Cell line engineering, Other Service)
    • 5.2.2. By Type (DNA base editing, RNA base editing)
    • 5.2.3. By Targeted Base (Cytosine base editing, Adenine base editing)
    • 5.2.4. By Application (Drug Discovery & Development, Agriculture, Veterinary)
    • 5.2.5. By End User (Pharmaceutical & Biotechnology Companies, Academic & Research Institutes, Contract Research Organizations)
    • 5.2.6. By Region
    • 5.2.7. By Company (2023)
  • 5.3. Market Map

6. North America Base Editing Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Product & Service
    • 6.2.2. By Type
    • 6.2.3. By Targeted Base
    • 6.2.4. By Application
    • 6.2.5. By End User
    • 6.2.6. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States Base Editing Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Product & Service
        • 6.3.1.2.2. By Type
        • 6.3.1.2.3. By Targeted Base
        • 6.3.1.2.4. By Application
        • 6.3.1.2.5. By End User
    • 6.3.2. Canada Base Editing Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Product & Service
        • 6.3.2.2.2. By Type
        • 6.3.2.2.3. By Targeted Base
        • 6.3.2.2.4. By Application
        • 6.3.2.2.5. By End User
    • 6.3.3. Mexico Base Editing Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Product & Service
        • 6.3.3.2.2. By Type
        • 6.3.3.2.3. By Targeted Base
        • 6.3.3.2.4. By Application
        • 6.3.3.2.5. By End User

7. Europe Base Editing Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Product & Service
    • 7.2.2. By Type
    • 7.2.3. By Targeted Base
    • 7.2.4. By Application
    • 7.2.5. By End User
    • 7.2.6. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. Germany Base Editing Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Product & Service
        • 7.3.1.2.2. By Type
        • 7.3.1.2.3. By Targeted Base
        • 7.3.1.2.4. By Application
        • 7.3.1.2.5. By End User
    • 7.3.2. United Kingdom Base Editing Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Product & Service
        • 7.3.2.2.2. By Type
        • 7.3.2.2.3. By Targeted Base
        • 7.3.2.2.4. By Application
        • 7.3.2.2.5. By End User
    • 7.3.3. Italy Base Editing Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Product & Service
        • 7.3.3.2.2. By Type
        • 7.3.3.2.3. By Targeted Base
        • 7.3.3.2.4. By Application
        • 7.3.3.2.5. By End User
    • 7.3.4. France Base Editing Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Product & Service
        • 7.3.4.2.2. By Type
        • 7.3.4.2.3. By Targeted Base
        • 7.3.4.2.4. By Application
        • 7.3.4.2.5. By End User
    • 7.3.5. Spain Base Editing Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Product & Service
        • 7.3.5.2.2. By Type
        • 7.3.5.2.3. By Targeted Base
        • 7.3.5.2.4. By Application
        • 7.3.5.2.5. By End User

8. Asia-Pacific Base Editing Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Product & Service
    • 8.2.2. By Type
    • 8.2.3. By Targeted Base
    • 8.2.4. By Application
    • 8.2.5. By End User
    • 8.2.6. By Country
  • 8.3. Asia-Pacific: Country Analysis
    • 8.3.1. China Base Editing Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Product & Service
        • 8.3.1.2.2. By Type
        • 8.3.1.2.3. By Targeted Base
        • 8.3.1.2.4. By Application
        • 8.3.1.2.5. By End User
    • 8.3.2. India Base Editing Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Product & Service
        • 8.3.2.2.2. By Type
        • 8.3.2.2.3. By Targeted Base
        • 8.3.2.2.4. By Application
        • 8.3.2.2.5. By End User
    • 8.3.3. Japan Base Editing Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Product & Service
        • 8.3.3.2.2. By Type
        • 8.3.3.2.3. By Targeted Base
        • 8.3.3.2.4. By Application
        • 8.3.3.2.5. By End User
    • 8.3.4. South Korea Base Editing Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Product & Service
        • 8.3.4.2.2. By Type
        • 8.3.4.2.3. By Targeted Base
        • 8.3.4.2.4. By Application
        • 8.3.4.2.5. By End User
    • 8.3.5. Australia Base Editing Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Product & Service
        • 8.3.5.2.2. By Type
        • 8.3.5.2.3. By Targeted Base
        • 8.3.5.2.4. By Application
        • 8.3.5.2.5. By End User

9. South America Base Editing Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Product & Service
    • 9.2.2. By Type
    • 9.2.3. By Targeted Base
    • 9.2.4. By Application
    • 9.2.5. By End User
    • 9.2.6. By Country
  • 9.3. South America: Country Analysis
    • 9.3.1. Brazil Base Editing Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Product & Service
        • 9.3.1.2.2. By Type
        • 9.3.1.2.3. By Targeted Base
        • 9.3.1.2.4. By Application
        • 9.3.1.2.5. By End User
    • 9.3.2. Argentina Base Editing Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Product & Service
        • 9.3.2.2.2. By Type
        • 9.3.2.2.3. By Targeted Base
        • 9.3.2.2.4. By Application
        • 9.3.2.2.5. By End User
    • 9.3.3. Colombia Base Editing Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Product & Service
        • 9.3.3.2.2. By Type
        • 9.3.3.2.3. By Targeted Base
        • 9.3.3.2.4. By Application
        • 9.3.3.2.5. By End User

10. Middle East and Africa Base Editing Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Product & Service
    • 10.2.2. By Type
    • 10.2.3. By Targeted Base
    • 10.2.4. By Application
    • 10.2.5. By End User
    • 10.2.6. By Country
  • 10.3. MEA: Country Analysis
    • 10.3.1. South Africa Base Editing Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Product & Service
        • 10.3.1.2.2. By Type
        • 10.3.1.2.3. By Targeted Base
        • 10.3.1.2.4. By Application
        • 10.3.1.2.5. By End User
    • 10.3.2. Saudi Arabia Base Editing Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Product & Service
        • 10.3.2.2.2. By Type
        • 10.3.2.2.3. By Targeted Base
        • 10.3.2.2.4. By Application
        • 10.3.2.2.5. By End User
    • 10.3.3. UAE Base Editing Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Product & Service
        • 10.3.3.2.2. By Type
        • 10.3.3.2.3. By Targeted Base
        • 10.3.3.2.4. By Application
        • 10.3.3.2.5. By End User

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Merger & Acquisition (If Any)
  • 12.2. Product Launches (If Any)
  • 12.3. Recent Developments

13. Porter's Five Forces Analysis

  • 13.1. Competition in the Industry
  • 13.2. Potential of New Entrants
  • 13.3. Power of Suppliers
  • 13.4. Power of Customers
  • 13.5. Threat of Substitute Product

14. Competitive Landscape

  • 14.1. Danaher Corporation
    • 14.1.1. Business Overview
    • 14.1.2. Company Snapshot
    • 14.1.3. Products & Services
    • 14.1.4. Financials (As Reported)
    • 14.1.5. Recent Developments
    • 14.1.6. Key Personnel Details
    • 14.1.7. SWOT Analysis
  • 14.2. Merck KGaA
  • 14.3. Maravai Intermediate Holdings, LLC
  • 14.4. GenScript Biotech Corporation
  • 14.5. Beam Therapeutics Inc.
  • 14.6. Intellia Therapeutics, Inc.
  • 14.7. Bio Palette Co., Ltd
  • 14.8. EdiGene, Inc.
  • 14.9. ProQR Therapeutics N.V.
  • 14.10.KromaTiD, Inc.

15. Strategic Recommendations

16. About Us & Disclaimer